Managed Access Programs for EXV811, Atrasentan
NCT07319585 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-01-22
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to EXV811, Atrasentan
Conditions
Interventions
- DRUG
-
Patients receive atrasentan
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Bosentan Use in Patients With Diabetic Nephropathy
NCT00638131 ·Status: TERMINATED ·Phase: PHASE3
-
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01336972 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Atorvastatin on Renal Function in Healthy Subjects During Normal and High Sodium Intake
NCT00678184 ·Status: COMPLETED ·Phase: PHASE4
-
Role of ARNi in Ventricular Remodeling in Hypertensive LVH
NCT03553810 ·Status: COMPLETED ·Phase: PHASE2
-
Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
NCT01691053 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers
NCT01115946 ·Status: COMPLETED ·Phase: PHASE1
-
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
NCT01424319 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986 ·Status: RECRUITING ·Phase: PHASE2
-
High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy
NCT00212901 ·Status: COMPLETED ·Phase: NA
-
CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
NCT01678794 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
NCT04183101 ·Status: RECRUITING ·Phase: PHASE2
-
Dietary Intervention in ADPKD on Tolvaptan
NCT03858439 ·Status: COMPLETED ·Phase: NA
-
Eplerenone in Systemic Right Ventricle
NCT00703352 ·Status: COMPLETED ·Phase: PHASE4
-
Renal Denervation for Resistant Hypertension
NCT01865240 ·Status: TERMINATED ·Phase: PHASE4
-
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
NCT00071331 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney
NCT04278495 ·Status: COMPLETED ·Phase: NA
-
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
NCT02847624 ·Status: COMPLETED
-
Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients
NCT00530595 ·Status: COMPLETED ·Phase: NA
-
Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients
NCT01503671 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)
NCT01638663 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
NCT03803124 ·Status: COMPLETED ·Phase: PHASE3
-
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
NCT02136862 ·Status: COMPLETED
-
Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions
NCT04736329 ·Status: COMPLETED ·Phase: NA
-
Atorvastatin and Sympathetic Activity in Chronic Kidney Disease
NCT01257009 ·Status: COMPLETED ·Phase: PHASE4
-
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
NCT00602004 ·Status: COMPLETED ·Phase: NA